Sutro Biopharma
STRO
99 hedge funds and large institutions have $39.6M invested in Sutro Biopharma in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 43 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $40M → $39.6M (-$342K)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
7.6% less ownership
Funds ownership: 73.36% → 65.75% (-7.6%)
12% less funds holding
Funds holding: 112 → 99 (-13)
30% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.29M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.93M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$1.66M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.26M |
| 5 |
Jane Street
New York
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.35M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.89M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.1M |
| 4 |
Goldman Sachs
New York
|
-$1.07M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$877K |
STRO Hedge Fund Activity: Q2 2025 in Review
99 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2025, worth a combined $39.6M — down 0.85% from $40M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of STRO and 30 opened new positions — a net loss of 13 holders — while 23 trimmed existing stakes and 22 added.
The largest buyer was Millennium Management, adding an estimated $3.29M. The largest seller was BlackRock, cutting an estimated $3.35M.
- 99 institutional investors held Sutro Biopharma (STRO) as of Q2 2025, down from 112 in Q1 2025.
- Funds reported $39.6M of Sutro Biopharma stock for Q2 2025, down 0.85% quarter-over-quarter.
- 30 funds opened new Sutro Biopharma positions in Q2 2025 and 43 closed out, a net change of -13 holders.
- The largest Sutro Biopharma buyer in Q2 2025 was Millennium Management, an estimated $3.29M added.
- The largest Sutro Biopharma seller in Q2 2025 was BlackRock, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2025.